Expert Consensus on the Clinical Application of Oral Small-molecule Antiviral Drugs Against COVID-19

Abstract Although COVID‑19 no longer constitutes a “public health emergency of international concern”, which still has being spreading around the world at a low level. Small molecule drugs are the main antiviral treatment for novel coronavirus recommended in China. Although a variety of small‑molecule antiviral drugs against COVID‑19 have been listed in China, there is no specific drug recommendation for special populations. Society of Bacterial Infection and Resistance of Chinese Medical Association, together with the National Clinical Research Center for Respiratory Disease, and the National Center for Respiratory Medicine, organized domestic experts in various fields such as respiratory, virology, infection, critical care, emergency medicine and pharmacy to release Expert Consensus on the Clinical Application of Oral Small‑Molecule Antiviral Drugs against COVID‑19. The main content of this consensus includes the introduction of seven small‑molecule antiviral drugs against COVID‑19, focusing on the drug recommendations for 14 special groups such as the elderly, patients with complicated chronic diseases, tumor patients, pregnant women, and children, and providing suggestions for clinicians to standardize drug use. Practice guideline registration: International Practice Guideline Registration for Transparency (PREPARE-2023CN617)